Analyst Ratings January 29, 2026

Citizens Lifts FTAI Aviation One-Year Target to $325, Cites Strong Growth and Cash-Flow Prospects

Analyst keeps Market Outperform rating as peers also raise targets following strategic deals and new business initiatives

By Priya Menon FTAI
Citizens Lifts FTAI Aviation One-Year Target to $325, Cites Strong Growth and Cash-Flow Prospects
FTAI

Citizens raised its one-year price objective on FTAI Aviation (NASDAQ:FTAI) to $325 from $230 and reiterated a Market Outperform rating, citing rapid share-price appreciation, upgraded 2026 forecasts and stronger valuation multiple assumptions. The firm grounded the target on a 25x EV/EBITDA multiple applied to its higher 2026 estimates and described the approach as conservative because it does not assume further expansion into 2027. Recent commercial agreements and product approvals have prompted other brokerages to lift their targets as well.

Key Points

  • Citizens raised its FTAI Aviation price target to $325 from $230 and reiterated a Market Outperform rating.
  • The new target is based on a 25x EV/EBITDA multiple applied to upgraded 2026 estimates; Citizens described its approach as conservative because it excludes 2027 growth.
  • Recent strategic moves - including a multi-year CFM International agreement, approval of a third PMA part and the launch of FTAI Power - prompted other brokerages to lift targets, affecting the aerospace and aftermarket MRO sectors.

Citizens on Thursday raised its price target for FTAI Aviation (NASDAQ:FTAI) to $325.00 from $230.00 and kept a Market Outperform rating on the stock. The firm noted the change while pointing to FTAI’s recent market performance and an upgraded forecast framework. This target falls above the current analyst high target of $335, with FTAI currently trading at a P/E ratio of 62.8.

Citizens described FTAI as "one of the most impressive stories in the public markets over the past few years," observing that the share price has climbed roughly 20 times since the company’s infrastructure spin-off in 2022. The firm cited the stock’s movement from about $15 in fall 2022 to recently touching $300 as evidence of that trajectory. Supporting data from InvestingPro, as referenced by Citizens, shows a 187% return over the past year and a 142.6% gain in the last six months.

The new one-year valuation is built on a 25x EV/EBITDA multiple applied to Citizens’ increased 2026 estimates, a step up from its prior 18.5x multiple. Citizens stated it views the higher multiple as "more than warranted" in light of the company’s fundamentals. The firm also emphasized that the valuation for the $325 target is based solely on 2026 expectations and does not incorporate any additional growth into 2027, calling that posture a conservative approach.

In laying out the rationale, Citizens highlighted several underlying drivers: a robust growth trajectory, a remixing of earnings, and improved free cash flow prospects. InvestingPro metrics referenced by the firm show FTAI posted 51.4% revenue growth and earned a strong financial health score, with analysts projecting continued sales expansion this year. Citizens directed readers to a Pro Research Report for extended detail on valuation metrics and growth potential.

Developments beyond Citizens’ note have also attracted analyst attention. FTAI announced a multi-year agreement with CFM International - the joint venture between GE Aerospace and Safran - to provide component and repair support for CFM56 engines. The stated objective of the agreement is to extend the life of those engines through optimized repair and maintenance offerings.

Following the CFM International announcement, several brokerages adjusted their views. RBC Capital raised its price target for FTAI Aviation to $350 while maintaining an Outperform rating. BTIG set a target of $335 and kept a Buy rating. Compass Point increased its target to $327, citing the potential financial contribution of FTAI Power, a recently launched business line that the firm said could generate meaningful incremental annual EBITDA.

Analysts at these firms characterized the partnership with CFM International, the approval of a third PMA part, and the launch of FTAI Power as strategically significant developments that bolster FTAI’s operational capabilities. Collectively, these items have contributed to elevated analyst confidence in the company’s strategic direction.


While Citizens’ updated target and peer upward adjustments reflect optimism about FTAI’s trajectory, the valuation approach remains narrowly focused on 2026 figures, intentionally excluding potential upside in 2027. That framing was presented by Citizens as a conservative stance even as it increased the EV/EBITDA multiple used in its modeling.

Investors watching FTAI will likely weigh the interplay between rapidly expanding expectations, near-term cash flow prospects and how recently announced commercial agreements translate into durable aftermarket revenue. The company’s recent operational milestones and third-party endorsements from multiple brokerages have clearly shifted the narrative, but Citizens’ note underscores that the one-year target is underpinned by explicit 2026 assumptions rather than multiyear extrapolation.

Risks

  • Valuation sensitivity - the one-year target relies on a 25x EV/EBITDA multiple applied to 2026 estimates, making the outcome sensitive to changes in EBITDA or the chosen multiple; this impacts investor returns in the aerospace-equipment and services sector.
  • Execution and conversion risk - assumptions about remixing of earnings and free cash flow depend on the company converting strategic agreements and new business lines into recurring revenue, which affects aftermarket and maintenance markets.
  • Concentration on a single-year view - Citizens’ framework excludes potential 2027 growth, so downside exists if 2026 performance falls short of elevated expectations, with market and financial-sector implications for equity valuations.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026